Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elan down on debt risk

ELN was down $2.07 (29%) to $5.09 on 34.8 million shares on Thursday on news that it will seek an extension in filing its 2002 annual report, which may

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE